Covalent fragment approaches targeting non-cysteine residues
- PMID: 37770315
- DOI: 10.1016/j.tips.2023.08.014
Covalent fragment approaches targeting non-cysteine residues
Abstract
Covalent fragment approaches combine advantages of covalent binders and fragment-based drug discovery (FBDD) for target identification and validation. Although early applications focused mostly on cysteine labeling, the chemistries of available warheads that target other orthosteric and allosteric protein nucleophiles has recently been extended. The range of different warheads and labeling chemistries provide unique opportunities for screening and optimizing warheads necessary for targeting non-cysteine residues. In this review, we discuss these recently developed amino-acid-specific and promiscuous warheads, as well as emerging labeling chemistries, which includes novel transition metal catalyzed, photoactive, electroactive, and noncatalytic methodologies. We also highlight recent applications of covalent fragments for the development of molecular glues and proteolysis-targeting chimeras (PROTACs), and their utility in chemical proteomics-based target identification and validation.
Keywords: amino acid labeling; covalent fragment; covalent labeling; covalent warheads; fragment-based drug discovery; photocatalysis.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests The authors have no interests to declare.
Similar articles
-
Covalent drug discovery using sulfur(VI) fluoride exchange warheads.Expert Opin Drug Discov. 2023 Jul;18(7):725-735. doi: 10.1080/17460441.2023.2218642. Epub 2023 May 27. Expert Opin Drug Discov. 2023. PMID: 37243622 Review.
-
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.J Med Chem. 2019 Jun 27;62(12):5673-5724. doi: 10.1021/acs.jmedchem.8b01153. Epub 2019 Jan 25. J Med Chem. 2019. PMID: 30565923 Review.
-
Electrophilic warheads in covalent drug discovery: an overview.Expert Opin Drug Discov. 2022 Apr;17(4):413-422. doi: 10.1080/17460441.2022.2034783. Epub 2022 Feb 6. Expert Opin Drug Discov. 2022. PMID: 35129005 Review.
-
A road map for prioritizing warheads for cysteine targeting covalent inhibitors.Eur J Med Chem. 2018 Dec 5;160:94-107. doi: 10.1016/j.ejmech.2018.10.010. Epub 2018 Oct 6. Eur J Med Chem. 2018. PMID: 30321804
-
Exploring Extended Warheads toward Developing Cysteine-Targeted Covalent Kinase Inhibitors.J Chem Inf Model. 2024 Dec 23;64(24):9517-9527. doi: 10.1021/acs.jcim.4c00890. Epub 2024 Dec 10. J Chem Inf Model. 2024. PMID: 39656065 Free PMC article.
Cited by
-
Size-Dependent Target Engagement of Covalent Probes.J Med Chem. 2025 Mar 27;68(6):6616-6632. doi: 10.1021/acs.jmedchem.5c00017. Epub 2025 Mar 18. J Med Chem. 2025. PMID: 40099438 Free PMC article.
-
Structure-based rational design of covalent probes.Commun Chem. 2025 Aug 12;8(1):242. doi: 10.1038/s42004-025-01606-y. Commun Chem. 2025. PMID: 40797071 Free PMC article. Review.
-
Identification of an Allene Warhead That Selectively Targets a Histidine Residue in the Escherichia coli Oxidoreductase Enzyme DsbA.ACS Med Chem Lett. 2025 Mar 22;16(4):625-630. doi: 10.1021/acsmedchemlett.5c00016. eCollection 2025 Apr 10. ACS Med Chem Lett. 2025. PMID: 40236539
-
The value of protein allostery in rational anticancer drug design: an update.Expert Opin Drug Discov. 2024 Sep;19(9):1071-1085. doi: 10.1080/17460441.2024.2384467. Epub 2024 Jul 28. Expert Opin Drug Discov. 2024. PMID: 39068599 Review.
-
Allosteric Covalent Inhibitors of the STAT3 Transcription Factor from Virtual Screening.ACS Med Chem Lett. 2025 May 6;16(6):991-997. doi: 10.1021/acsmedchemlett.4c00622. eCollection 2025 Jun 12. ACS Med Chem Lett. 2025. PMID: 40529081
Publication types
LinkOut - more resources
Full Text Sources